Sonoma Pharmaceuticals (NASDAQ:SNOA) Releases Earnings Results, Beats Estimates By $0.15 EPS

Sonoma Pharmaceuticals (NASDAQ:SNOAGet Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.15, MarketWatch Earnings reports. Sonoma Pharmaceuticals had a negative return on equity of 58.35% and a negative net margin of 41.24%. The business had revenue of $3.14 million for the quarter.

Sonoma Pharmaceuticals Stock Performance

Shares of NASDAQ:SNOA opened at $0.16 on Friday. The stock’s fifty day simple moving average is $0.18 and its 200-day simple moving average is $0.49. Sonoma Pharmaceuticals has a 52-week low of $0.12 and a 52-week high of $1.58.

Hedge Funds Weigh In On Sonoma Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in SNOA. State Street Corp acquired a new position in Sonoma Pharmaceuticals in the second quarter valued at $27,000. Two Sigma Securities LLC acquired a new position in Sonoma Pharmaceuticals in the second quarter valued at $56,000. Finally, Renaissance Technologies LLC increased its stake in Sonoma Pharmaceuticals by 25.5% in the second quarter. Renaissance Technologies LLC now owns 75,767 shares of the company’s stock valued at $221,000 after purchasing an additional 15,400 shares during the last quarter. 3.41% of the stock is currently owned by institutional investors and hedge funds.

Sonoma Pharmaceuticals Company Profile

(Get Free Report)

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.

Featured Articles

Earnings History for Sonoma Pharmaceuticals (NASDAQ:SNOA)

Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with's FREE daily email newsletter.